$LNAI News

Lunai Bioworks' BioSymetrics And BrainStorm Therapeutics Announce Strategic Collaboration And LOI Integrating AI Discovery, Human Brain Organoid Modeling, And In Vivo Validation To Generate Differentiated Neurology Assets For Pharmaceutical Partnering And Development

Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942K

Lunai Bioworks Approves Reverse Stock Split At Ratio Of 1-For-3 To 1-For-30

Lunai Bioworks' Subsidiary Inks Letter Of Intent With Geneial Over Strategic Partnership In Rare Neurological Disorders

Lunai Bioworks shares are trading higher after the company announced it entered into a a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment.

Lunai Bioworks shares are trading higher after the company announced it entered into a a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment.

Lunai Bioworks' BioSymetrics Launches AI-Enabled Chemical Threat Detection Collaboration, Advancing Dual-Use Biodefense Through Commercial Engagement

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

What's Behind The Jump In Lunai Bioworks Stock?

Lunai Bioworks shares are trading higher after the company announced that it will acquire blood-brain barrier delivery technology and central nervous system Alzheimer's drug assets from the Clemann Group for $20 million.

Lunai Bioworks Executes $20M Transaction To Acquire Blood-Brain Barrier Delivery Technology And Central Nervous System Alzheimer's Drug Assets From Clemann Group

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Lunai Bioworks Launches Pathfinder Consortium To Accelerate Chemical Antidote Development To 3-Year Timeline

Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada On Feb 27, 2026

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

Lunai Bioworks: Fiscal Q2 Earnings Snapshot

Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY

Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

12 Health Care Stocks Moving In Wednesday's Intraday Session

Lunai Bioworks, Inc. Issues Letter to Shareholders